Thu.Jun 27, 2024

article thumbnail

Billionaire Sackler family can't get legal immunity as part of Purdue bankruptcy deal, Supreme Court rules

Fierce Pharma

Years of negotiations and legal proceedings surrounding a high-dollar opioid settlement for Purdue Pharma have reached a dead end at the U.S. Supreme Court. | Years of negotiations and legal proceedings surrounding a high-dollar opioid settlement for Purdue Pharma have reached a dead end at the U.S. Supreme Court.

Pharma 241
article thumbnail

What Do Experts Make of Risant Health’s Newest Acquisition?

MedCity News

While it it’s too early to judge the success of Kaiser Permanente’s Risant Health, the company’s first two acquisitions show a commitment to adjoining organizations with a strong focus on population health — as well as a dedication to spreading Kaiser’s value-based care delivery models across the country. The post What Do Experts Make of Risant Health’s Newest Acquisition?

108
108
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

In bispecific rivalry, AbbVie’s Epkinly follows Roche’s Lunsumio into follicular lymphoma

Fierce Pharma

With Regeneron’s treatment delayed, AbbVie is expanding its T-cell engager competition against Roche in blood cancer with a new FDA approval. | With Regeneron's treatment delayed, AbbVie is expanding its T-cell engager competition against Roche in blood cancer with a new FDA approval.

article thumbnail

Don’t call it a comeback: Biotech’s CNS resurgence forges Big Pharma connections

PharmaVoice

Neuroscience pipelines are reawakening as biotechs prove to the pharma giants that the field is still worth the investment.

Pharma 122
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Fierce Pharma Asia—Daiichi, Merck's FDA rejection; Wegovy's expansion; Takeda CEO's hunt for China deals

Fierce Pharma

The FDA rejected Daiichi Sankyo and Merck's HER3 antibody-drug conjugate. Novo Nordisk's weight loss star Wegovy secured approval in China. | The FDA rejected Daiichi Sankyo and Merck's HER3 antibody-drug conjugate. Novo Nordisk's weight-loss star Wegovy secured approval in China. After two large licensing deals, Takeda's CEO is open to more partnerships with Chinese biotechs.

FDA 178
article thumbnail

Verona Pharma Drug With Dual Mechanism Lands FDA Approval in COPD

MedCity News

Verona Pharma’s COPD drug Ohtuvayre is a single small molecule that blocks two targets to bring patients both bronchodilation and anti-inflammatory effects. Verona executives contend their inhalable drug has key advantages over the last novel COPD medication, the orally administered roflumilast. The post Verona Pharma Drug With Dual Mechanism Lands FDA Approval in COPD appeared first on MedCity News.

Pharma 104

More Trending

article thumbnail

Blue Shield of California Launches New Way for Members to Interact with Health Info

MedCity News

Blue Shield of California unveiled its new Member Health Record on Wednesday. It allows members to access their health information in one place within the insurer’s app or website. The post Blue Shield of California Launches New Way for Members to Interact with Health Info appeared first on MedCity News.

Insurance 100
article thumbnail

FDA go-ahead for Verona Ohtuvayre transforms US COPD exacerbator market

Pharmaceutical Technology

Data showed that Ohtuvayre significantly improved dyspnea compared to placebo in as little as six weeks and maintained this over 24 weeks.

article thumbnail

Purdue’s bankruptcy plan in tatters as SCOTUS says no

pharmaphorum

SCOTUS rejects bankruptcy deal that would settle opioid litigation against Purdue Pharma, but also protect the Sackler family from liability.

Pharma 105
article thumbnail

Formation Bio secures $372m funds for AI-driven drug platform

Pharmaceutical Technology

Formation Bio has secured $372m in Series D funding to bolster its drug pipeline and expand its AI-driven drug development platform.

97
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

The Impact of GI Disorders on Women’s Mental Health

MedCity News

GI disorders are complex, disruptive, and immensely stressful, with physiological, psychological, and sociological implications. The post The Impact of GI Disorders on Women’s Mental Health appeared first on MedCity News.

article thumbnail

2seventy bio completes $40m haemophilia A program deal with Novo Nordisk

Pharmaceutical Technology

US-based 2seventy bio has completed an asset purchase agreement (APA) to divest its haemophilia A candidate to Novo Nordisk.

98
article thumbnail

Biden’s ‘March-In-Rights’ Proposal Undermines 40-Year-Old Policy, and Endangers Life-Saving Innovation

MedCity News

It is crucial that we preserve the unique public-private partnership framework that drives innovation in our country by ensuring that the Bayh-Dole Act remains intact. The post Biden’s ‘March-In-Rights’ Proposal Undermines 40-Year-Old Policy, and Endangers Life-Saving Innovation appeared first on MedCity News.

article thumbnail

Novo Nordisk’s ocedurenone Phase III flop costs company $816m

Pharmaceutical Technology

NovoNordisk acquired the hypertension and kidney disease drug ocedurenone from KBP Biosciences in 2023 as part of a $1.3bn deal.

95
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

McKesson, Independent Pharmacy Cooperative Reach Drug Supply Agreement

Pharmaceutical Commerce

The deal offers member pharmacies two pricing options, which will take effect Aug. 1.

105
105
article thumbnail

FDA turns down MSD, Daiichi Sankyo HER3 ADC for lung cancer

pharmaphorum

FDA rejects MSD, Daiichi Sankyo’s HER3-targeted ADC patritumab deruxtecan because of problems at a third-party manufacturer

FDA 109
article thumbnail

Addressing Sales Enablement Pain Points with AI Solutions

Quantified

Introduction In the ever shifting landscape of sales, enablement is crucial for business success. Sales enablement provides sales teams with the tools, resources, and information they need to engage buyers and close deals effectively. However, several pain points can hinder these efforts. Leveraging artificial intelligence (AI) can significantly mitigate these challenges, transforming sales enablement into a more efficient and effective process.

Sales 65
article thumbnail

Drug approval roundup – May/June 2024

European Pharmaceutical Review

Considering recent EU and US approvals, there has been a continued trend of exciting innovative therapies reaching market, demonstrating promise for a range of hard-to-treat-diseases. In May and June, regulatory approvals have so far included treatments for rare disorders as well as in oncology, such as blood, endometrial and colorectal cancers. Looking back briefly to 2023, within the cell and gene therapy space, the US Food and Drug Administration (FDA) approved marketing authorisations for se

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

England, Denmark back CSL’s haemophilia B gene therapy

pharmaphorum

CSL Behring's gene therapy Hemgenix for haemophilia B has been backed for reimbursement in England and Denmark.

104
104
article thumbnail

Pharma Pulse 6/27/24: Pharmacy Deserts & Underserved/Rural Communities, GoodRx Launches New “Prescription Cost Tracker” & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 101
article thumbnail

European Commission Approves Metastatic Colorectal Cancer Monotherapy

PharmaTech

Fruzaqla was previously approved for use in patients with metastatic colorectal cancer in the US in November 2023.

article thumbnail

FDA Issues Complete Response Letter to Merck and Daiichi Sankyo for Patritumab Deruxtecan for Advanced, Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

PharmExec

The Complete Response Letter was issued as a result of inspection findings at a third-party manufacturing facility, unrelated to patritumab deruxtecan’s efficacy or safety in patients with advanced or metastatic EGFR-mutated non-small cell lung cancer.

Safety 52
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Novo Nordisk Aims to Invest $4.1 Billion to Expand Manufacturing Capacity in US

PharmaTech

This $4.1 billion investment to build a second fill/finish manufacturing facility in Clayton, N.C., boosts Novo Nordisk's current 2024 investments in production to $6.8 billion.

article thumbnail

FDA Approves Genmab’s Epkinly to Treat Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy

PharmExec

Approval of Epkinly was based on results from the Phase I/II EPCORE trial in patients with relapsed or refractory follicular lymphoma who have already completed two or more lines of systemic therapy.

FDA 52
article thumbnail

The Association Between 340B Program Involvement and Availability of Hospital Services

Pharmaceutical Commerce

A longitudinal observational study examined whether the program was related to access to hospital-based services, while determining if that association differs by hospital ownership.

52
article thumbnail

Empowering Financial Advisors: Scott Burrows, Inspirational Business Keynote Speaker

Scott Burrows

In the fast-paced world of financial services, where each day presents fresh challenges and intense competition, I stand as a beacon of inspiration and expert guidance. My journey of resilience and triumph empowers financial service organizations and their teams to cultivate a belief system that conquers any obstacle while embracing change. Through compelling storytelling and practical insights, I vividly illustrate how enduring principles such as Vision, Mindset, and Grit lead to remarkable ach

article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Citius Pharmaceuticals Co-Founder and CEO Talks Promising Results from a Phase III Clinical Trial for Mino-Lok, a Treatment Designed to Salvage Catheters in Patients with Central-Line Associated Infections

PharmExec

In an interview with Pharm Exec Associated Editor Don Tracy, Leonard Mazur, Co-Founder, CEO, Citius Pharmaceuticals, discusses recent topline results from the pivotal Phase III Clinical Trial of Mino-Lok, which works to salvage catheters infections.

article thumbnail

Kite to Evaluate Cellares’ Manufacturing Platform for Wider Use

PharmaTech

No timetable was given for the length of the planned evaluation or when data would be available, but Kite intends to use the information to expand its manufacturing options.

article thumbnail

Pharmacy Closure Contributors & Long-Term Consequences

PharmExec

In this part of his Pharmaceutical Executive video interview, Michael Abrams, Managing Partner, Numerof & Associates, identifies the main factors contributing to closures of pharmacies big and small and some potential long-term consequences for public health if they continue.

article thumbnail

FDA reveals diversity action plan guide for clinical trials

pharmaphorum

FDA reveals diversity action plan guide for clinical trials Phil.

FDA 105
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A